Frequently Asked Questions
The global compounding chemotherapy market was valued at USD 0.6 Billion in 2022.
The compounding chemotherapy market is anticipated to grow at a CAGR of 6.3% between 2023 and 2030, reaching USD 0.92 Billion in 2030.
Chemotherapeutic is the leading segment by dose type, holding over 62% share in terms of value in 2022.
The pharmaceutical dosage alteration (PDA) segment governs the demand for compounding chemotherapy worldwide, holding a massive share of over 68% in 2022.
The gravimetric automated compounding device segment will post the highest CAGR in the projected period.
Asia Pacific is fuelling the rapid growth of the compounding chemotherapy industry, with an over one-third share in 2022.
The top players include Omnicell Inc, Dedalus S.P.A., Baxter International Inc, and Equashield LLC. Other major players include Pfizer Inc, Metrix Company S.A., Icon Group, and Loccioni Group.
The increasing prevalence of cancer, developments in chemotherapy medications and technologies, and the growing demands for personalized and targeted cancer therapies are the primary market drivers of the compounding chemotherapy industry.
The major market restraints of the compounding chemotherapy industry include stringent regulatory requirements, the high cost of chemotherapy treatments, and the potential side effects and toxicity of chemotherapy drugs.
The major market opportunities in the compounding chemotherapy industry include the development of novel chemotherapy formulations and delivery methods, the integration of precision medicine approaches, and the expanding healthcare infrastructure in emerging markets.